EGFR and non-small cell lung carcinoma: The discovery of activating mutations of the EGFR gene in NSCLC and the subsequent development of the TKIs belonging to the first (gefitinib, erlotinib), the second (afatinib, dacomitinib), and the third generation (osimertinib) has initiated the era of personalized medicine for the management of NSCLC.